Active Biotech: Interim Phase Ib Results from NeoTX
Research Note
2023-04-17
11:59
NeoTX, the partner of Active Biotech developing naptumomab estafenatox, has presented new results from the phase I/IIa trial combining naptumomab with durvalumab at the AACR Annual Meeting 2023.
RR
Richard Ramanius
Disclosures and disclaimers